Telo Genomics (TELO.V) Action Cours

Telo Genomics Corp. is a biotechnology company, which engages in the development and commercialization of technological products designed to personalize treatment plans for patients who have specific conditions. The company is headquartered in Toronto, Ontario. The company went IPO on 2012-02-15. The firm is focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for diseases that display genomic instability. Its lead product, TeloView SMM, is a high-complexity molecular assay available for clinical use to provide information to physicians treating patients with Smoldering Multiple Myeloma. Through proprietary telomere-based analysis, TeloView SMM selects high-risk SMM patients who are likely to benefit from earlier treatment intervention while identifying the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment. The TeloView SMM assay has a potential total addressable market of over 500,000 tests per year.